Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | RRM1 | P23921 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869136 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2SIRT6SIRT1TLR2 | |
| SCHEMBL12087709 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2SIRT6SIRT1TLR2 | |
| SCHEMBL13339080 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2SIRT6SIRT1TLR2 | |
| SCHEMBL20687052 | 0.98 | SLC6A5 (0.63) | SLC6A5EPHX2SIRT6SIRT1TLR2 | |
| SCHEMBL16553006 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 | |
| SCHEMBL16553399 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 | |
| SCHEMBL12667547 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 | |
| SCHEMBL13561440 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 | |
| SCHEMBL16553400 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 | |
| SCHEMBL16553128 | 0.96 | SLC6A5 (0.60) | SLC6A5EPHX2GRIA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216227-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216227-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120277289-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | MARINA BIOTECH, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277289-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | MARINA BIOTECH, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2496260-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | Marina Biotech, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057020-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | MARINA BIOTECH, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277289-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | XPA, NPPA, LNPEP | SLC6A5 2540/4885EPHX2 2224/4885SIRT6 1779/4885 |
| US-20170216227-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | LNPEP, LDLR, XPA | SLC6A5 2329/4885EPHX2 2878/4885SIRT6 2189/4885 |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | LNPEP, LDLR, XPA | SLC6A5 2329/4885EPHX2 2878/4885SIRT6 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.